Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of “Buy” from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned a consensus rating of “Buy” from the sixteen research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, twelve have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $32.6364.

Several brokerages have recently commented on DNLI. Morgan Stanley decreased their target price on Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating for the company in a research report on Monday, August 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Denali Therapeutics in a report on Monday, September 8th. JPMorgan Chase & Co. increased their target price on shares of Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. TD Cowen upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research report on Monday, July 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, October 8th.

Institutional Trading of Denali Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale boosted its position in Denali Therapeutics by 7.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 64,210 shares of the company’s stock valued at $935,000 after purchasing an additional 4,410 shares during the period. Victory Capital Management Inc. lifted its stake in Denali Therapeutics by 8.1% in the first quarter. Victory Capital Management Inc. now owns 41,627 shares of the company’s stock valued at $566,000 after buying an additional 3,119 shares during the last quarter. Y Intercept Hong Kong Ltd boosted its holdings in shares of Denali Therapeutics by 52.2% during the first quarter. Y Intercept Hong Kong Ltd now owns 54,813 shares of the company’s stock valued at $745,000 after acquiring an additional 18,807 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Denali Therapeutics during the first quarter worth about $254,000. Finally, Knights of Columbus Asset Advisors LLC grew its position in shares of Denali Therapeutics by 2.7% during the first quarter. Knights of Columbus Asset Advisors LLC now owns 40,275 shares of the company’s stock worth $548,000 after acquiring an additional 1,058 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Price Performance

Shares of DNLI stock opened at $15.60 on Thursday. The firm has a fifty day moving average of $15.08 and a two-hundred day moving average of $14.68. The firm has a market cap of $2.29 billion, a P/E ratio of -5.36 and a beta of 1.39. Denali Therapeutics has a 1-year low of $10.57 and a 1-year high of $33.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.79 and a quick ratio of 9.79.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, November 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.02. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the business posted ($0.63) earnings per share. As a group, research analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.